CytRx Corporation (CYTR) Presents Interim Clinical Trial Results for Aldoxorubicin Combination
CytRx (NASDAQ: CYTR) today presented interim results from its ongoing phase 1b/2 trail of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas, pushing shares higher in morning trade. At the European Society for Medical Oncology (ESMO) 2016 Congress being held in Copenhagen, Denmark, CytRx reported that: over 25% of sarcoma patients achieved a partial response for the target lesion while 61% had prolonged stable disease; six patients with unresectable tumors achieved greater than 50% tumor shrinkage, allowing some of them to become eligible for surgery; and there were no signs of cardiotoxicity, including in patients that received approximately…